Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study

被引:25
作者
Ozer, Kerem [1 ]
Cooper, Alison M. [1 ]
Ahn, Lily P. [1 ]
Waggonner, Cassidy R. [1 ]
Blevins, Thomas C. [1 ]
机构
[1] Texas Diabet & Endocrinol, 6500 N Mopac Expy 200, Austin, TX 78731 USA
关键词
Fast acting insulin aspart; Medtronic 670G hybrid closed loop; Type; 1; diabetes; DELIVERY-SYSTEM; ADULTS;
D O I
10.1089/dia.2020.0500
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This is a single-center randomized open label active-controlled crossover trial comparing efficacy and safety of fast acting insulin aspart (FA) (FIASP(R)) versus insulin aspart (IAsp) (NovoLog(R)) when used in the Medtronic 670G system in auto mode in patients with type 1 diabetes. Forty patients were randomized to either IAsp or FA. Each treatment period was 7 weeks and a standardized meal test was administered 6 weeks after the start of each treatment period. The primary endpoint was postprandial glucose (PPG) increment after the meal test at 1 h. Treatment with FA using the MiniMed 670G hybrid closed loop (HCL) led to a greater reduction in 1-h postprandial glucose increase compared with treatment with IAsp during the standardized mixed meal test. Change in glucose: [estimated treatment difference (ETD +/- standard deviation [SD]); 95% confidence interval]: 70.27 (+/- 17.36) mg/dL (3.9 +/- 1.0 mmol/L) with FA versus 98.42 (+/- 17.36) mg/dL (5.5 +/- 1.0 mmol/L) with IAsp (P = 0.008). Patients spent 1.81% (P = 0.016) more time (equivalent to 26 min per day) in the 70-180 mg/dL (3.89-9.99 mmol/L) range with FA than with IAsp. The entire sample spent only 0.5% of time <54 mg/dL (<3.0 mmol/L) range. The increment in the 1 h postmeal test glucose was significantly lower with FA versus IAsp. FA in a HCL setting is safe and effective with patients spending more time in the 70-180 mg/dL (3.89-9.99 mmol/L) target range than with IAsp. Trial registration: Clinicaltrials.gov identifier: NCT03977727.
引用
收藏
页码:286 / 292
页数:7
相关论文
共 14 条
  • [1] Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange
    Agiostratidou, Gina
    Anhalt, Henry
    Ball, Dana
    Blonde, Lawrence
    Gourgari, Evgenia
    Harriman, Karen N.
    Kowalski, Aaron J.
    Madden, Paul
    McAuliffe-Fogarty, Alicia H.
    McElwee-Malloy, Molly
    Peters, Anne
    Raman, Sripriya
    Reifschneider, Kent
    Rubin, Karen
    Weinzimer, Stuart A.
    [J]. DIABETES CARE, 2017, 40 (12) : 1622 - 1630
  • [2] American Diabetes Association, 2020, DIABETES CARE, V43, pS6676
  • [3] Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes
    Amiel, Stephanie A.
    Aschner, Pablo
    Childs, Belinda
    Cryer, Philip E.
    de Galan, Bastiaan E.
    Heller, Simon R.
    Frier, Brian M.
    Gonder-Frederick, Linda
    Jones, Timothy
    Khunti, Kamlesh
    Leiter, Lawrence A.
    McCrimmon, Rory J.
    Luo, Yingying
    Seaquist, Elizabeth R.
    Vigersky, Robert
    Zoungas, Sophia
    [J]. DIABETOLOGIA, 2017, 60 (01) : 3 - 6
  • [4] [Anonymous], PROTOCOL HYBRID CLOS
  • [5] Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
    Battelino, Tadej
    Danne, Thomas
    Bergenstal, Richard M.
    Amiel, Stephanie A.
    Beck, Roy
    Biester, Torben
    Bosi, Emanuele
    Buckingham, Bruce A.
    Cefalu, William T.
    Close, Kelly L.
    Cobelli, Claudio
    Dassau, Eyal
    DeVries, J. Hans
    Donaghue, Kim C.
    Dovc, Klemen
    Doyle, Francis J.
    Garg, Satish
    Grunberger, George
    Heller, Simon
    Heinemann, Lutz
    Hirsch, Irl B.
    Hovorka, Roman
    Jia, Weiping
    Kordonouri, Olga
    Kovatchev, Boris
    Kowalski, Aaron
    Laffel, Lori
    Levine, Brian
    Mayorov, Alexander
    Mathieu, Chantal
    Murphy, Helen R.
    Nimri, Revital
    Norgaard, Kirsten
    Parkin, Christopher G.
    Renard, Eric
    Rodbard, David
    Saboo, Banshi
    Schatz, Desmond
    Stoner, Keaton
    Urakami, Tatsuiko
    Weinzimer, Stuart A.
    Phillip, Moshe
    [J]. DIABETES CARE, 2019, 42 (08) : 1593 - 1603
  • [6] Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes
    Bergenstal, Richard M.
    Garg, Satish
    Weinzimer, Stuart A.
    Buckingham, Bruce A.
    Bode, Bruce W.
    Tamborlane, William V.
    Kaufman, Francine R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (13): : 1407 - 1408
  • [7] Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
    Bode, Bruce W.
    Johnson, Joseph A.
    Hyveled, Liselotte
    Tamer, Soren C.
    Demissie, Marek
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (01) : 25 - +
  • [8] Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial
    Dovc, Klemen
    Piona, Claudia
    Mutlu, Guel Yesiltepe
    Bratina, Natasa
    Bizjan, Barbara Jenko
    Lepej, Dusanka
    Nimri, Revital
    Atlas, Eran
    Muller, Ido
    Kordonouri, Olga
    Biester, Torben
    Danne, Thomas
    Phillip, Moshe
    Battelino, Tadej
    [J]. DIABETES CARE, 2020, 43 (01) : 29 - 36
  • [9] Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
    Garg, Satish K.
    Weinzimer, Stuart A.
    Tamborlane, William V.
    Buckingham, Bruce A.
    Bode, Bruce W.
    Bailey, Timothy S.
    Brazg, Ronald L.
    Ilany, Jacob
    Slover, Robert H.
    Anderson, Stacey M.
    Bergenstal, Richard M.
    Grosman, Benyamin
    Roy, Anirban
    Cordero, Toni L.
    Shin, John
    Lee, Scott W.
    Kaufman, Francine R.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (03) : 155 - 163
  • [10] Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
    Heise, T.
    Hoevelmann, U.
    Brondsted, L.
    Adrian, C. L.
    Nosek, L.
    Haahr, H.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (07) : 682 - 688